Contact Information

37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG

We Are Available 24/ 7. Call Now.
Ozempic Settles the Obesity Debate: It's Biology Over Willpower
Business

Ozempic Settles the Obesity Debate: It's Biology Over Willpower

Weight-loss drugs affect the brain in ways that help researchers understand how the body regulates weight. Source link

Pfizer’s Covid Boost Crashes to Earth
Business

Pfizer’s Covid Boost Crashes to Earth

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law.

Venture Capitalist Seeks to Spur Drug Development for Rare Autoimmune Disease
Business

Venture Capitalist Seeks to Spur Drug Development for Rare Autoimmune Disease

Venture capitalist Luke Evnin has financed several successful biotechnology startups that develop treatments for cancer. Now he is encouraging drugmakers to tackle another disease: a rare autoimmune condition that

Pfizer Misses Revenue Expectations, Bets on Drug Launches to Ease Shortfall
Business

Pfizer Misses Revenue Expectations, Bets on Drug Launches to Ease Shortfall

The company is rolling out 19 products or new uses within 18 months, CEO Albert Bourla said. Source link

Obesity Drugs Won't Starve These Other Potential Blockbusters
Finances

Obesity Drugs Won't Starve These Other Potential Blockbusters

Stocks of developers of fatty liver disease treatments had been on a tear until results from Eli Lilly’s medication were published last week. Source link

Moderna, Merck Show Progress Toward Cancer Vaccines
Business

Moderna, Merck Show Progress Toward Cancer Vaccines

An mRNA shot helped prevent relapse in high-risk melanoma patients. Source link

Ozempic, Wegovy and Mounjaro Spark a Weight-Loss and Diet Industry Identity Crisis
Business

Ozempic, Wegovy and Mounjaro Spark a Weight-Loss and Diet Industry Identity Crisis

Weight-loss businesses, which long pushed calorie-counting and willpower, are grappling with the surging popularity of new drugs. Source link

FTC Rejects Illumina's $7 Billion Deal for Cancer-Test Developer Grail
Business

FTC Rejects Illumina's $7 Billion Deal for Cancer-Test Developer Grail

The agency said the combination would hurt competition for cancer-detection tests while raising prices. Source link